Analysts' Actions: ACN AMZN FB GS XOM

NEW YORK (TheStreet) -- CHANGE IN RATINGS

Accenture ( ACN) was initiated with a buy rating at UBS. Based on bookings, revenues should see reacceleration, and EPS growth of 17% is expected in the second half of the year, UBS said. Price target is $85.

Actavis ( ACT) was upgraded to buy at TheStreet Ratings.

Amazon ( AMZN) was initiated with a neutral rating at UBS. The company's secular positioning is a positive, but operating costs remain a headwind given investment mode, UBS said. Price target is $275.

Sothebys ( BID) was upgraded to buy at TheStreet Ratings.

Buffalo Wild Wings ( BWLD) was initiated with a neutral rating at Credit Suisse. $92 price target. Acquisitions add risk to the model, Credit Suisse said.

CME Group ( CME) was downgraded at Credit Suisse to neutral from outperform. Valuation call, Credit Suisse said.

DaVita HCP ( DVA) was upgraded at Deutsche Bank to buy from hold. $136 price target. Less concerned about HCP's year-over-year earnings trajectory, Deutsche said.

eBay ( EBAY) was upgraded at Topeka Capital Markets to buy from hold. $65 price target. Management should continue to execute on its growth strategy, Topeka Capital Markets said.

EZCorp ( EZPW) was downgraded at FBR Capital Markets to underperform from market perform. $17.50 price target. Company is highly leveraged to the U.S. and gold, FBR Capital Markets said.

Facebook ( FB) was initiated with a neutral rating at UBS. Monetization of mobile, a focus on protecting the user experience, and high investment needs will create a drag on performance in 2013, UBS said. Price target is $26.

F5 Networks ( FFIV) was upgraded at Robert Baird to outperform from neutral. Checks show better demand in traditional markets and security, Baird said.

GNC Holdings ( GNC) was upgraded at Deutsche Bank to buy from hold. $50 price target. Investor fear seems more than discounted into shares, Deutsche said.

Groupon ( GRPN) was initiated with a sell rating at UBS. Uncertainty about the business model, recent operating trends and changing management drive the cautious stance, UBS said. Price target is $4.40.

Goldman Sachs ( GS) was downgraded at Bank of America/Merrill Lynch to neutral from buy. Valuation call, based on a $155 price target, BofA/Merrill said.

Hewlett-Packard ( HPQ) was downgraded at Goldman Sachs to sell from neutral. Earnings expectations should fall, Goldman said. $16 price target.

Linear Technology ( LLTC) was downgraded to hold from buy, Stifel Nicolaus said. Checks show slower order growth, Stifel Nicolaus said.

Morgan Stanley ( MS) was downgraded at Credit Suisse to neutral from outperform. Valuation call, Credit Suisse said.

Rackspace Hosting ( RAX) was downgraded at Wells Fargo to market perform. Impacting the company is cloud computing, which is somewhat cannibalizing managed hosting growth, as are reduced bandwith prices, Wells Fargo said. Valuation range is now $47 to $52.

Charles Schwab ( SCHW) was downgraded at Credit Suisse to neutral from outperform. Don't expect more earnings expansion in the capital markets space, Credit Suisse said.

Suntrust Banks ( STI) was downgraded at Credit Suisse to neutral from outperform. Estimates were also cut, given a slower recovery, Credit Suisse said.

Texas Instruments ( TXN) was downgraded at Stifel Nicolaus to hold from buy. Orders appears to have slowed down, Stifel Nicolaus said.

World Acceptance ( WRLD) was downgraded at FBR Capital Markets to market perform from outperform. Valuation call, FBR Capital Markets said.

Exxon Mobil ( XOM) was downgraded at Oppenheimer to perform from outperform. Company lacks near-term catalysts, Oppenheimer said.

Yahoo! ( YHOO) was initiated with a buy rating at UBS. Potential monetization of its Asian Internet holdings drive the rating, the core business is viewed as having a fair value, UBS said. Price target is $27.

STOCK COMMENTS/EPS CHANGES

Apple ( AAPL) was cut from the Conviction Buy List at Goldman Sachs. New products are not driving continued growth, Goldman said. $575 price target.

Actavis ( ACT) estimates, target were boosted at Morgan Stanley. Shares are now seen reaching $101. Estimates were also increased, following the generic Pulmicort settlement, Morgan Stanley said. Overweight rating.

Amgen ( AMGN) price target was raised at Oppenheimer. Shares are now seen reaching $100. Industry valuations are rising, Oppenheimer said. Perform rating.

Biogen ( BIIB) price target and estimates were increased at Bernstein. Estimates were increased to account for a higher-than-expected price for recently approved Tecfidera, said Bernstein. Price target was increased to $201.

Sandisk ( SNDK) estimates, price target were increased at Nomura. Estimates were raised through 2014. Company is seeing higher demand and is leveraged to a weaker yen, Nomura said. Buy rating and new $60 price target.

WisdomTree ( WETF) price target and estimates were raised at Citigroup to reflect higher AUM and lower franchise risk. New price target is $13.50.

U.S. Steel ( X) price target and estimates were cut at Bank of America/Merrill Lynch. Estimates were reduced to reflect a greater margin squeeze as iron ore prices fall and costs remain fixed, said Bank of America/Merrill Lynch. Price target was reduced to $14.

>To submit a news tip, email: tips@thestreet.com.

READERS ALSO LIKE:


Follow TheStreet on Twitter and become a fan on Facebook.

This article was written by a staff member of TheStreet.

More from Stocks

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

3 Great Stock Market Sectors Millennials Should Invest In

3 Great Stock Market Sectors Millennials Should Invest In

Why Millennials Are Ditching Stocks for ETFs

Why Millennials Are Ditching Stocks for ETFs

Trump's 'Space Force' Could Launch a $1 Trillion Industry, Morgan Stanley Says

Trump's 'Space Force' Could Launch a $1 Trillion Industry, Morgan Stanley Says

Abiomed Stock Should Rise Some 12% From Here, Piper Jaffray Analyst Says

Abiomed Stock Should Rise Some 12% From Here, Piper Jaffray Analyst Says